Results 351 to 360 of about 436,330 (367)

Janus kinase 2 inhibitors in myeloproliferative disorders

Expert Opinion on Investigational Drugs, 2010
JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit its activity particularly in myeloproliferative disorders (MPD) harboring JAK2(V617F) mutations.We discuss the physiopathology of the JAK2 signaling pathway and
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.   +15 more
openaire   +3 more sources

Janus kinases inhibitors for treating patients with rhupus

Joint Bone Spine, 2020
HIGHLIGHTS • baricitinib and tofacitinib are effective in patients with Rhupus • JAK inhibitors are an alternative option in patients with refractory SLE • JAK inhibitors have a steroid-sparing effect in patients with ...
Garufi C., Mancuso S., Spinelli F. R., Truglia S., Ceccarelli F., Alessandri C., Conti F.   +6 more
openaire   +2 more sources

Janus kinases inhibitors

Cahiers Santé Médecine Thérapeutique, 2022
El Mehdi Boudhar, M El Mandour, Abdelhafid Elguich, Hajar Sahimi, Hasna Hassikou   +4 more
openaire   +1 more source

Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors

Current Pharmaceutical Design, 2004
Here we discuss the therapeutic potential of Janus kinase 3 (JAK3) inhibitors as a new class of immunomodulatory agents with immunosuppressive, anti-inflammatory, anti-allergic, anti-thrombotic and anti-leukemic properties. JAKs are abundantly expressed in primary leukemic cells from children with ALL (acute lymphoblastic leukemia) and are crucial for ...
M, Cetkovic-Cvrlje, H E, Tibbles
openaire   +2 more sources

Thromboembolism and Janus Kinase Inhibitors

Drug Safety, 2020
Fowzia Ibrahim, David L. Scott
openaire   +3 more sources

Janus Kinase (JAK) Inhibitors

2022
Courtney E. Heron, Lindsay C. Strowd, Steven R. Feldman   +2 more
openaire   +1 more source

What are Janus kinase (JAK) inhibitors?

Pediatric Dermatology
JAK inhibitors are medications that can lower inflammation in the body. Some inflammation can help the body to fight infections or injuries. But too much inflammation is also the cause of certain skin problems. JAK inhibitors can help by lowering inflammation to improve skin diseases.
openaire   +2 more sources

[Janus kinase inhibitors for skin disorders].

Dermatologie (Heidelberg, Germany)
Immune factors such as interferon‑ɣ and interleukin 4 belong to the group of cytokines that are dependent on type I/II receptors for their signal transmission. Upon activation, these receptors transmit their signal to the cell nucleus and, thus, modulate gene transcription via a signaling cascade consisting of Janus kinases (JAK).
Farzan, Solimani, Kamran, Ghoreschi
openaire   +1 more source

Questioning the Janus Kinase (JAK) Inhibitors!

C59. POTRERO HILL: CASE REPORTS IN PULMONARY HYPERTENSION, 2022
H. Hussain, S. Faryad, D. Taneja
openaire   +1 more source

Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box

Clinical Rheumatology, 2022
D. Misra, Gaurav K Pande, V. Agarwal
semanticscholar   +1 more source